Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02879617
Title A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Liza Villaruz, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST